General Pathology — MCQs

General Pathology Indian Medical PG Practice Questions and MCQs

Question 1301: Factor Xa is necessary for the conversion of prothrombin to thrombin?

A. Only in the extrinsic pathway
B. Only in the intrinsic pathway
C. As part of both extrinsic and intrinsic pathways (Correct Answer)
D. Only if the normal blood clotting cascade is inhibited

Explanation: **Explanation:** The coagulation cascade is traditionally divided into the intrinsic and extrinsic pathways, both of which converge onto a single **Common Pathway**. **Why the correct answer is right:** Factor Xa is the central protease of the common pathway. Regardless of whether the cascade is initiated by tissue injury (Extrinsic/Tissue Factor pathway) [1] or surface contact (Intrinsic pathway), both pathways culminate in the activation of **Factor X to Factor Xa**. Once activated, Factor Xa complexed with Factor Va, calcium, and phospholipids (the **Prothrombinase Complex**) catalyzes the conversion of **Prothrombin (Factor II) to Thrombin (Factor IIa)** [1]. Therefore, Factor Xa is indispensable for thrombin generation in both pathways. **Analysis of Incorrect Options:** * **Options A & B:** These are incorrect because they are too restrictive. While the *activation* of Factor X can occur via the extrinsic (VIIa/TF) or intrinsic (tenase complex) routes, the *function* of Factor Xa remains the same: driving the common pathway. * **Option D:** This is factually incorrect. Factor Xa is a physiological requirement for normal hemostasis, not a compensatory mechanism for inhibition. **NEET-PG High-Yield Pearls:** * **The Prothrombinase Complex:** Consists of Factor Xa (enzyme), Factor Va (cofactor), Phospholipids, and Ca²⁺. * **Rate-Limiting Step:** The conversion of Prothrombin to Thrombin by Factor Xa is often considered the most critical step in clot formation [1]. * **Pharmacology Link:** **Rivaroxaban** and **Apixaban** are Direct Factor Xa inhibitors, while **Fondaparinux** is an indirect inhibitor (via Antithrombin III). * **Lab Correlation:** Deficiencies in the common pathway (Factors X, V, II, or I) will prolong both **PT (Prothrombin Time)** and **aPTT (activated Partial Thromboplastin Time)**. **References:** [1] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Hemodynamic Disorders, Thromboembolic Disease, and Shock, pp. 126-128.

Question 1302: S100 is a marker used in the diagnosis of which of the following conditions, EXCEPT?

A. Melanoma
B. Schwannoma
C. Histiocytoma
D. Basal cell carcinoma (Correct Answer)

Explanation: **Explanation:** **S100** is a highly sensitive, acidic calcium-binding protein found in cells derived from the **neural crest**. It is a classic immunohistochemical (IHC) marker used to identify tumors of melanocytic, neural, and cartilaginous origin. **Why Basal Cell Carcinoma (BCC) is the correct answer:** BCC is a common skin cancer derived from the non-keratinizing cells of the basal layer of the **epidermis** (ectodermal origin) [1]. Unlike melanocytes or neural cells, basal cells do not express S100. Therefore, S100 is characteristically **negative** in BCC, making it a useful negative marker to differentiate it from amelanotic melanoma [1]. **Analysis of Incorrect Options:** * **Melanoma:** S100 is the most sensitive (though not the most specific) marker for melanocytic tumors. It is used to screen for melanoma, especially the spindle cell and amelanotic variants. * **Schwannoma:** Since Schwann cells are derived from the neural crest, they show strong and diffuse positivity for S100 [2]. It is the gold standard marker for peripheral nerve sheath tumors. * **Histiocytoma (specifically Langerhans Cell Histiocytosis):** S100 is a key marker for Langerhans cells and dendritic cells. While "Histiocytoma" is a broad term, in the context of pathology exams, S100 positivity is a hallmark of Langerhans cell lineages. **High-Yield Clinical Pearls for NEET-PG:** * **S100 Positive Tissues:** Melanocytes, Schwann cells, Chondrocytes, Adipocytes, and Langerhans cells. * **Specific Melanoma Markers:** While S100 is sensitive, **HMB-45** and **Melan-A** are more specific for melanoma. * **Differential Diagnosis:** S100 is vital in distinguishing **Schwannoma** (S100 diffuse/strong) from **Neurofibroma** (S100 focal/weak) [2]. * **Other S100+ Tumors:** Chondrosarcoma, Liposarcoma, and Astrocytomas. **References:** [1] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. The Skin, pp. 1158-1162. [2] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Peripheral Nerves and Skeletal Muscles, pp. 1249-1250.

Question 1303: What is true about caspases?

A. Involved in apoptosis (Correct Answer)
B. Cause necrosis
C. Involved in pain pathway
D. Are cytokine inhibitors

Explanation: **Explanation:** **Caspases** (Cysteine-aspartic proteases) are the central executioners of **apoptosis** (programmed cell death) [1]. They exist as inactive zymogens (pro-caspases) and are activated through two main pathways: the **Intrinsic (Mitochondrial) pathway** and the **Extrinsic (Death Receptor) pathway** [1]. Once activated, they cleave specific proteins at aspartic acid residues, leading to DNA fragmentation and cell shrinkage [1]. * **Option A (Correct):** Caspases are categorized into **Initiators** (Caspase 8, 9, 10) and **Executioners** (Caspase 3, 6, 7) [1]. Caspase-3 is the most common executioner caspase that initiates the final stages of apoptosis. * **Option B (Incorrect):** Necrosis is typically an unregulated, accidental cell death characterized by cell swelling and membrane rupture, usually independent of the caspase cascade. * **Option C (Incorrect):** The pain pathway involves neurotransmitters like Substance P and prostaglandins, not caspases. * **Option D (Incorrect):** While some caspases (like Caspase-1) are involved in inflammatory responses (processing IL-1̠), they are **activators** of the inflammatory response (via the Inflammasome), not inhibitors. **High-Yield Clinical Pearls for NEET-PG:** * **Caspase-8:** Associated with the Extrinsic pathway (Fas/FasL) [2]. * **Caspase-9:** Associated with the Intrinsic pathway (Cytochrome c/Apaf-1) [1]. * **Caspase-3:** The "Point of No Return" in apoptosis; it cleaves ICAD (Inhibitor of Caspase-Activated DNase), allowing DNase to fragment DNA. * **Caspase-1:** Known as Interleukin-1 Converting Enzyme (ICE), it is involved in **Pyroptosis** (inflammatory programmed cell death). **References:** [1] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Cellular Responses to Stress and Toxic Insults: Adaptation, Injury, and Death, pp. 64-67. [2] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Cellular Responses to Stress and Toxic Insults: Adaptation, Injury, and Death, p. 67.

Question 1304: A trait in which the parents are clinically normal and only siblings are affected, with males and females affected in equal proportions, is characteristic of which inheritance pattern?

A. Autosomal Dominant (AD)
B. Autosomal Recessive (AR) (Correct Answer)
C. X-linked Dominant (XLD)
D. X-linked Recessive (XLR)

Explanation: ### Explanation **Correct Answer: B. Autosomal Recessive (AR)** The scenario described is a classic presentation of **Autosomal Recessive** inheritance [1]. The key features provided are: 1. **Clinically normal parents:** This indicates that the parents are asymptomatic carriers (heterozygotes) [1]. 2. **Siblings affected:** Since the parents are carriers, there is a 25% recurrence risk for each sibling [1]. 3. **Equal distribution in males and females:** This confirms the trait is **autosomal** rather than sex-linked [1]. In AR disorders, the trait typically skips generations (horizontal transmission). Most metabolic disorders (enzymopathies) follow this pattern [2], [3]. --- ### Why the other options are incorrect: * **A. Autosomal Dominant (AD):** These traits show **vertical transmission** (affected individuals in every generation). Usually, at least one parent must be affected for a child to manifest the disease. * **C. X-linked Dominant (XLD):** While both sexes are affected, there is a distinct sex bias. An affected father will pass the trait to **all** of his daughters and **none** of his sons. * **D. X-linked Recessive (XLR):** This pattern shows a strong **male predominance**. Females are usually asymptomatic carriers, and the trait is typically passed from a carrier mother to her sons. --- ### NEET-PG High-Yield Pearls: * **Consanguinity:** AR disorders are more common in consanguineous marriages (mating between close relatives) [1]. * **Enzyme vs. Structural:** Most **enzyme deficiencies** are AR (e.g., Phenylketonuria, Albinism, Lysosomal storage diseases), while most **structural protein defects** are AD (e.g., Marfan syndrome, Achondroplasia) [2], [3]. * **Exceptions:** Two notable X-linked recessive metabolic disorders are **Hunter Syndrome** and **Fabry Disease** (most other storage diseases are AR). * **Quasidominance:** When a homozygous recessive individual mates with a heterozygote, the pedigree may mimic an AD pattern. **References:** [1] Cross SS. Underwood's Pathology: A Clinical Approach. 6th ed. (Basic Pathology) introduces the student to key general principles of pathology, both as a medical science and as a clinical activity with a vital role in patient care. Part 2 (Disease Mechanisms) provides fundamental knowledge about the cellular and molecular processes involved in diseases, providing the rationale for their treatment. Part 3 (Systematic Pathology) deals in detail with specific diseases, with emphasis on the clinically important aspects., pp. 53-54. [2] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Genetic Disorders, pp. 150-151. [3] Cross SS. Underwood's Pathology: A Clinical Approach. 6th ed. (Basic Pathology) introduces the student to key general principles of pathology, both as a medical science and as a clinical activity with a vital role in patient care. Part 2 (Disease Mechanisms) provides fundamental knowledge about the cellular and molecular processes involved in diseases, providing the rationale for their treatment. Part 3 (Systematic Pathology) deals in detail with specific diseases, with emphasis on the clinically important aspects., pp. 57-58.

Question 1305: Chemotherapeutic drugs can cause which of the following types of cell death?

A. Only necrosis
B. Only apoptosis
C. Both necrosis and apoptosis (Correct Answer)
D. Anoikis

Explanation: **Explanation:** The correct answer is **Both necrosis and apoptosis (Option C)** because the mechanism of cell death induced by chemotherapeutic agents is dose-dependent and cell-cycle dependent [2]. 1. **Apoptosis:** Most chemotherapy drugs (e.g., Cisplatin, Etoposide) work by inducing DNA damage or inhibiting metabolic pathways [1]. This triggers the **p53 pathway**, leading to the activation of the intrinsic (mitochondrial) apoptotic pathway [1]. This is the intended "programmed" cell death in cancer therapy. 2. **Necrosis:** If the dose of the chemotherapeutic agent is very high (toxic levels) or if the drug causes rapid, severe metabolic disruption or membrane damage, the cell cannot complete the energy-dependent process of apoptosis [2]. Instead, it undergoes **accidental, unregulated necrosis**, characterized by cell swelling and membrane rupture [2]. **Analysis of Incorrect Options:** * **Option A & B:** These are incorrect because chemotherapy does not exclusively use one pathway. While apoptosis is the primary goal, necrosis occurs as a secondary effect of high-dose toxicity or "secondary necrosis" if apoptotic bodies are not cleared. * **Option D (Anoikis):** This is a specific subtype of apoptosis induced by the loss of cell-matrix interactions (detachment). While relevant to metastasis, it is not the primary mechanism by which systemic chemotherapy kills cells. **High-Yield NEET-PG Pearls:** * **p53 Status:** The efficacy of many chemo-agents depends on functional p53 to trigger apoptosis. Mutations in p53 often lead to chemoresistance. * **Mitotic Catastrophe:** A form of cell death occurring during mitosis, often seen with drugs like Paclitaxel (microtubule stabilizers), which can eventually lead to either necrosis or apoptosis. * **Necroptosis:** Some newer studies suggest certain drugs can also trigger "programmed necrosis" (necroptosis), further supporting the "Both" category. **References:** [1] Cross SS. Underwood's Pathology: A Clinical Approach. 6th ed. (Basic Pathology) introduces the student to key general principles of pathology, both as a medical science and as a clinical activity with a vital role in patient care. Part 2 (Disease Mechanisms) provides fundamental knowledge about the cellular and molecular processes involved in diseases, providing the rationale for their treatment. Part 3 (Systematic Pathology) deals in detail with specific diseases, with emphasis on the clinically important aspects., pp. 101-102. [2] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Cellular Responses to Stress and Toxic Insults: Adaptation, Injury, and Death, pp. 55-56, 62-63.

Question 1306: All of the following statements are true regarding hypertrophy, except:

A. Occurs due to synthesis and assembly of additional intracellular components.
B. There is an increase in the size of the cells.
C. Cells capable of division respond to stress by hypertrophy and hyperplasia.
D. There is an increase in the number of cells. (Correct Answer)

Explanation: ### Explanation **Hypertrophy** is defined as an increase in the size of cells, resulting in an increase in the size of the organ [1]. It occurs when cells are incapable of dividing but are subjected to increased workload or growth factor stimulation [2]. **1. Why Option D is the Correct Answer (The "Except"):** Hypertrophy involves an increase in cell **size**, not cell **number** [1]. An increase in the number of cells is the definition of **Hyperplasia** [3]. While hypertrophy and hyperplasia often occur together, they are distinct cellular adaptations [3]. **2. Analysis of Incorrect Options:** * **Option A:** True. Hypertrophy is not just cellular swelling (edema); it is an active process involving the increased synthesis of structural proteins and organelles (like myofilaments) to meet increased functional demands [2]. * **Option B:** True. This is the fundamental definition of hypertrophy [1]. The increased workload leads to gene activation and protein synthesis, expanding the cell volume [2]. * **Option C:** True. Cells with regenerative capacity (e.g., uterine smooth muscle during pregnancy or hepatocytes) typically respond to stress using both hypertrophy and hyperplasia simultaneously [1], [3]. **3. Clinical Pearls for NEET-PG:** * **Pure Hypertrophy:** Occurs in **permanent cells** (cardiac muscle and skeletal muscle) because they cannot divide [3]. A classic example is Left Ventricular Hypertrophy (LVH) due to hypertension [4]. * **Mechanism:** Triggered by mechanical sensors (stretch), growth factors (IGF-1), and vasoactive agents (Endothelin-1, Angiotensin II) [2]. * **Physiological vs. Pathological:** * *Physiological:* Uterus in pregnancy (both hypertrophy and hyperplasia) [2]; Skeletal muscle in bodybuilders (hypertrophy only). * *Pathological:* Cardiac hypertrophy due to valvular disease or hypertension [4]. * **Key Distinction:** If the stress persists in the heart, hypertrophy reaches a limit, leading to degenerative changes, fragmentation of contractile proteins, and ultimately, heart failure [3]. **References:** [1] Cross SS. Underwood's Pathology: A Clinical Approach. 6th ed. (Basic Pathology) introduces the student to key general principles of pathology, both as a medical science and as a clinical activity with a vital role in patient care. Part 2 (Disease Mechanisms) provides fundamental knowledge about the cellular and molecular processes involved in diseases, providing the rationale for their treatment. Part 3 (Systematic Pathology) deals in detail with specific diseases, with emphasis on the clinically important aspects., pp. 85-87. [2] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Cellular Responses to Stress and Toxic Insults: Adaptation, Injury, and Death, pp. 45-46. [3] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Cellular Responses to Stress and Toxic Insults: Adaptation, Injury, and Death, pp. 46-47. [4] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. The Heart, p. 536.

Question 1307: A diabetic male presented with seizures. Radiological examination shows a lesion. Histopathological examination shows liquefactive necrosis. What is the most important mechanism responsible for this?

A. Ischemic
B. Mechanical
C. Pressure
D. Enzymatic degradation (Correct Answer)

Explanation: ***Enzymatic degradation*** - Liquefactive necrosis, common in the brain (e.g., in stroke or brain abscess as suggested by the presentation in a **diabetic** patient), is defined by the complete dissolution of dead tissue into a viscous liquid mass [1]. - This dissolution is mediated by the robust release of **hydrolytic enzymes** from inflammatory cells (like **neutrophils** in an abscess) and the deceased parenchymal cells themselves, leading to the formation of a fluid-filled cavity [1]. *Mechanical* - Mechanical injury (trauma) is a *cause* of cell death and tissue damage, but it does not describe the specific biochemical process of liquefying the dead cells. - Mechanical factors primarily lead to **coagulative necrosis** initially if blood supply is compromised, or immediate cellular disruption, which is then processed by other mechanisms. *Ischemic* - Ischemia (lack of blood flow) is a common *cause* of necrosis (e.g., cerebral infarction), which often results in liquefactive necrosis in the CNS due to its high lipid content [1]. - While ischemia is the initiating event in many cases of liquefaction (especially stroke), the actual conversion of solid dead tissue into a liquid consistency requires the action of catabolic **enzymes**. *Pressure* - Pressure usually leads to generalized **atrophy** or localized **ischemia** (e.g., pressure sores or hydrocephalus), but it is not the fundamental molecular mechanism defining liquefactive necrosis. - Severe localized pressure that compromises microcirculation leads to ischemic injury, and the subsequent type of necrosis (liquefactive or coagulative) depends on the affected organ. **References:** [1] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. The Central Nervous System, pp. 1268-1269.

Question 1308: FBN1 gene mutation is seen in which of the following genetic disorders?

A. Homocystinuria
B. von Hippel-Lindau syndrome
C. Ehlers-Danlos syndrome
D. Marfan syndrome (Correct Answer)

Explanation: ***Marfan syndrome***- The **FBN1 gene** (located on chromosome 15) encodes the protein **fibrillin-1**, a major component of the extracellular matrix, deficiency of which leads to the clinical manifestations of Marfan syndrome.- **Fibrillin-1** is integral to the formation of elastic fibers; its defect causes issues in the skeletal, ocular, and cardiovascular systems [1].*Ehlers-Danlos syndrome*- This group of disorders is primarily caused by defects in **collagen synthesis** (e.g., **COL5A1**, **COL3A1**) or processing, leading to joint hypermobility and skin hyperextensibility [2].- It is not typically associated with the **FBN1** mutation.*Homocystinuria*- This disorder is an autosomal recessive metabolic error usually caused by a deficiency of the enzyme **cystathionine beta-synthase** (CBS) [3].- It involves abnormal metabolism of **methionine** and **cysteine**, leading to high levels of **homocysteine**, and is not linked to **FBN1**.*von Hippel-Lindau syndrome*- This is a predisposition syndrome caused by a mutation in the **VHL tumor suppressor gene** (located on chromosome 3).- It predisposes patients to various tumors, including **hemangioblastomas** and **renal cell carcinoma**, and has no association with **FBN1**. **References:** [1] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Genetic Disorders, pp. 153-154. [2] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Genetic Disorders, pp. 155-156. [3] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Genetic Disorders, pp. 150-151.

Question 1309: Which genetic syndrome is caused by a deletion of the short arm of chromosome 5 (5p deletion)?

A. Edward syndrome
B. Turner syndrome
C. Patau syndrome
D. Cri-du-chat syndrome (Correct Answer)

Explanation: ***Cri-du-chat syndrome*** - This syndrome is classically defined by a partial terminal deletion of the short arm of chromosome 5, designated as **5p deletion**. - Key clinical features include severe **intellectual disability**, **microcephaly**, and the characteristic high-pitched, monotonic **cat-like cry** that gives the syndrome its name. *Edward syndrome* - Edward syndrome is caused by an extra copy of chromosome 18 (**Trisomy 18**) [1]. - Clinical findings are often severe, including **micrognathia**, overlapping fingers, and **rocker-bottom feet** [1]. *Patau syndrome* - Patau syndrome is caused by an extra copy of chromosome 13 (**Trisomy 13**) [1]. - It is associated with severe midline defects such as **holoprosencephaly**, **cleft lip and palate**, and **polydactyly** [1]. *Turner syndrome* - Turner syndrome is a sex chromosome abnormality resulting from the absence of one X chromosome (45,X), making it a form of **monosomy X** [2]. - It primarily affects females, causing features like **short stature**, primary **amenorrhea** due to streak ovaries, and a **webbed neck** [2]. **References:** [1] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Genetic Disorders, pp. 168-169. [2] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Genetic Disorders, pp. 175-177.

Question 1310: Which of the following is pro-apoptotic?

A. Bcl-2
B. Bax (Correct Answer)
C. Bcl-xL
D. Mcl-1

Explanation: ***Bax*** - Bax is a key **pro-apoptotic** effector protein from the Bcl-2 family [1]. Upon activation by stress signals, it translocates to the mitochondria and forms pores in the outer membrane [2]. - This pore formation, along with Bak, leads to **Mitochondrial Outer Membrane Permeabilization (MOMP)**, which releases **cytochrome c** and initiates the intrinsic caspase cascade of apoptosis [3]. *Bcl-2* - Bcl-2 is the prototypical **anti-apoptotic** protein that prevents apoptosis by binding to and inhibiting pro-apoptotic proteins like Bax and Bak [2]. - By preventing MOMP, it maintains mitochondrial integrity and is often overexpressed in cancers, such as follicular lymphoma, contributing to cell survival [2]. *Bcl-xL* - Bcl-xL is another major **anti-apoptotic** protein in the Bcl-2 family, with a function very similar to Bcl-2 [2]. - It promotes cell survival by sequestering pro-apoptotic BH3-only proteins and preventing the activation of Bax and Bak. *Mcl-1* - Mcl-1 (Myeloid cell leukemia-1) is a critical **anti-apoptotic** protein that is essential for the survival of various cell types [2]. - Its primary role is to inhibit apoptosis by neutralizing pro-apoptotic proteins, and its high levels are often associated with tumor progression and resistance to chemotherapy [2]. **References:** [1] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Cellular Responses to Stress and Toxic Insults: Adaptation, Injury, and Death, pp. 65-67. [2] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Neoplasia, p. 310. [3] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Cellular Responses to Stress and Toxic Insults: Adaptation, Injury, and Death, pp. 64-65.

Practice by Chapter

Cell Injury and Cell Death

Practice Questions

Adaptations of Cellular Growth

Practice Questions

Accumulations and Deposits

Practice Questions

Acute and Chronic Inflammation

Practice Questions

Tissue Repair and Wound Healing

Practice Questions

Hemodynamic Disorders

Practice Questions

Genetic Disorders

Practice Questions

Environmental Pathology

Practice Questions

Nutritional Diseases

Practice Questions

Molecular Basis of Disease

Practice Questions

Want unlimited practice?

Get full access to all questions, explanations, and performance tracking.

Start For Free